{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T19:19:49Z","timestamp":1778786389697,"version":"3.51.4"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82425104"],"award-info":[{"award-number":["82425104"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC3400501"],"award-info":[{"award-number":["2022YFC3400501"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC3400504"],"award-info":[{"award-number":["2022YFC3400504"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejmech.2025.118097","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T06:26:25Z","timestamp":1756535185000},"page":"118097","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Discovery and SAR study of highly selective and potent 1,2,4-oxadiazole-based S1PR1 agonists"],"prefix":"10.1016","volume":"300","author":[{"given":"Tianyu","family":"Ye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinling","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxian","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenjiang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honglin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1957-973X","authenticated-orcid":false,"given":"Lili","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118097_bib1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1124\/pr.54.2.265","article-title":"International union of pharmacology. XXXIV. Lysophospholipid receptor nomenclature","volume":"54","author":"Chun","year":"2002","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejmech.2025.118097_bib2","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.05702-11","article-title":"G protein-coupled receptor signaling and sphingosine-1-phosphate play a phylogenetically conserved role in endocrine pancreas morphogenesis","author":"Serafimidis","year":"2011","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118097_bib3","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20101474","article-title":"Chemorepulsion by blood S1P regulates osteoclast precursor mobilization and bone remodeling in vivo","author":"Ishii","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejmech.2025.118097_bib4","doi-asserted-by":"crossref","DOI":"10.1007\/s40265-024-02094-5","article-title":"Targeting the sphingosine-1-phosphate pathway: new opportunities in inflammatory bowel disease management","author":"Kitsou","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118097_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.635995","article-title":"Ceramides and sphingosino-1-phosphate in obesity","author":"Juchnicka","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejmech.2025.118097_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.prostaglandins.2021.106584","article-title":"Role of sphingosine-1-phosphate mediated signalling in systemic lupus erythematosus","author":"Tian","year":"2021","journal-title":"Prostag. Other Lipid Mediat."},{"key":"10.1016\/j.ejmech.2025.118097_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(21)00244-0","article-title":"Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions","author":"McGinley","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2025.118097_bib8","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1146\/annurev-immunol-081519-083952","article-title":"Finding a way out: S1P signaling and immune cell migration","volume":"38","author":"Baeyens","year":"2020","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2025.118097_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/science.1139221","article-title":"Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate","author":"Pappu","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.118097_bib10","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar5551","article-title":"Sphingosine 1-phosphate: lipid signaling in pathology and therapy","volume":"366","author":"Cartier","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.118097_bib11","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/ni1545","article-title":"Finding a way out: lymphocyte egress from lymphoid organs","volume":"8","author":"Schwab","year":"2007","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ejmech.2025.118097_bib12","first-page":"1","article-title":"Regulatory T cell and endothelial cell crosstalk","author":"Piao","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2025.118097_bib13","article-title":"Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs","author":"Cyster","year":"2011","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2025.118097_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/science.1070238","article-title":"Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists","author":"Mandala","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.118097_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/nature02284","article-title":"Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1","author":"Matloubian","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118097_bib16","article-title":"The vascular S1P gradient-cellular sources and biological significance","author":"Hla","year":"2008","journal-title":"Biochim. Biophys. Acta BBA - Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.ejmech.2025.118097_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/nri1650","article-title":"Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network","author":"Rosen","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2025.118097_bib18","article-title":"The potential capacities of FTY720: novel therapeutic functions, targets, and mechanisms against diseases","author":"Liu","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118097_bib19","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.6b01575","article-title":"Modulators of sphingosine-1-phosphate pathway biology: recent advances of sphingosine-1-phosphate receptor 1 (S1P1) agonists and future perspectives","author":"Dyckman","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118097_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/nrd4099","article-title":"Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond","author":"Kunkel","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118097_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115182","article-title":"S1PR1 modulators in multiple sclerosis: efficacy, safety, comparison, and chemical structure insights","volume":"250","author":"Kandjani","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118097_bib22","first-page":"1","article-title":"GPCR drug discovery: new agents, targets and indications","author":"Lorente","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118097_bib23","doi-asserted-by":"crossref","DOI":"10.1146\/annurev-pharmtox-010818-021358","article-title":"Fingolimod: lessons learned and new opportunities for treating multiple sclerosis and other disorders","author":"Chun","year":"2019","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejmech.2025.118097_bib24","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","author":"Kappos","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118097_bib25","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","author":"Cohen","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118097_bib26","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejmech.2025.118097_bib27","doi-asserted-by":"crossref","DOI":"10.1007\/s40265-017-0692-6","article-title":"The ocular manifestations of drugs used to treat multiple sclerosis","author":"Heath","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118097_bib28","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200164","article-title":"Multiple sclerosis, disease-modifying therapies, and infections, neurol","author":"Langer-Gould","year":"2023","journal-title":"Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.ejmech.2025.118097_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/acn3.52017","article-title":"Sphingosine 1-phosphate receptor modulators in multiple sclerosis treatment: a practical review","author":"Coyle","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.ejmech.2025.118097_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2016.04.002","article-title":"Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS)","author":"Meissner","year":"2016","journal-title":"Mult. Scler. Relat. Disord"},{"key":"10.1016\/j.ejmech.2025.118097_bib31","doi-asserted-by":"crossref","DOI":"10.1111\/cns.12283","article-title":"Vagomimetic effects of fingolimod: physiology and clinical implications","author":"Vanoli","year":"2014","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.ejmech.2025.118097_bib32","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.103.062828","article-title":"Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes","author":"Forrest","year":"2004","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2025.118097_bib33","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/S1474-4422(13)70102-9","article-title":"Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study","volume":"12","author":"Selmaj","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejmech.2025.118097_bib34","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/j.1476-5381.2012.02061.x","article-title":"The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate","volume":"167","author":"Gergely","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118097_bib35","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s40263-020-00771-z","article-title":"Siponimod: a review in secondary progressive multiple sclerosis","volume":"34","author":"Scott","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejmech.2025.118097_bib36","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial","volume":"18","author":"Comi","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejmech.2025.118097_bib37","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1111\/bph.13476","article-title":"Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity","volume":"173","author":"Scott","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118097_bib38","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/jcph.887","article-title":"Results from the first-in-human study with ozanimod, a novel, selective sphingosine-1-phosphate receptor modulator","volume":"57","author":"Tran","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118097_bib39","article-title":"Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus","volume":"13","author":"Meadows","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.118097_bib40","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1136\/jnnp-2013-307282","article-title":"Oral ponesimod in relapsing\u2013remitting multiple sclerosis: a randomised phase II trial","volume":"85","author":"Olsson","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ejmech.2025.118097_bib41","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1021\/jm100181s","article-title":"2-Imino-thiazolidin-4-one derivatives as potent, Orally active S1P1 receptor agonists","volume":"53","author":"Bolli","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118097_bib42","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1021\/ml500389m","article-title":"Discovery of APD334: design of a clinical stage functional antagonist of the sphingosine-1-phosphate-1 receptor","volume":"5","author":"Buzard","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118097_bib43","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s40265-024-01997-7","article-title":"Etrasimod: first approval","volume":"84","author":"Shirley","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118097_bib44","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1474-4422(16)00018-1","article-title":"Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial","volume":"15","author":"Cohen","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejmech.2025.118097_bib45","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1365-2125.2012.04400.x","article-title":"Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects","volume":"75","author":"Legangneux","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118097_bib46","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bcp.12129","article-title":"Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P receptor modulator, in the first-in-human study","volume":"76","author":"Brossard","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118097_bib47","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/14656566.2023.2178898","article-title":"An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis","volume":"24","author":"Dumitrescu","year":"2023","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2025.118097_bib48","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.370","article-title":"Cenerimod, a novel selective S1P1 receptor modulator with unique signaling properties","volume":"5","author":"Piali","year":"2017","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.ejmech.2025.118097_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1380975","article-title":"Icanbelimod (CBP-307), a next-generation Sphingosine-1-phosphate receptor modulator, in healthy men: pharmacokinetics, pharmacodynamics, safety, and tolerability in a randomized trial in Australia","volume":"15","author":"Lickliter","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2025.118097_bib50","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2117716119","article-title":"Structural insights into sphingosine-1-phosphate receptor activation","volume":"119","author":"Yu","year":"2022","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejmech.2025.118097_bib51","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1021\/acs.jmedchem.6b00089","article-title":"Potent and selective agonists of sphingosine 1-phosphate 1 (S1P1): discovery and SAR of a novel isoxazole based series","volume":"59","author":"Watterson","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118097_bib52","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/cpdd.98","article-title":"Safety, pharmacokinetics, pharmacodynamics, and bioavailability of GSK2018682, a sphingosine-1-phosphate receptor modulator, in healthy volunteers","volume":"3","author":"Xu","year":"2014","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.ejmech.2025.118097_bib53","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1021\/acs.jmedchem.1c01979","article-title":"Discovery of novel sphingosine-1-phosphate-1 receptor agonists for the treatment of multiple sclerosis","volume":"65","author":"Park","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118097_bib54","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/cjoc.202200392","article-title":"Design, synthesis and biological evaluation of potent and selective S1PR1 agonists for the treatment of ulcerative colitis","volume":"40","author":"He","year":"2022","journal-title":"Chin. J. Chem."},{"key":"10.1016\/j.ejmech.2025.118097_bib55","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/1087057113502234","article-title":"No differences observed among multiple clinical S1P1 receptor agonists (functional antagonists) in S1P1 receptor down-regulation and degradation","volume":"19","author":"Lukas","year":"2014","journal-title":"SLAS Discov"},{"key":"10.1016\/j.ejmech.2025.118097_bib56","unstructured":"WO_2015039587_A1, (n.d.)."},{"key":"10.1016\/j.ejmech.2025.118097_bib57","doi-asserted-by":"crossref","first-page":"9082","DOI":"10.1074\/jbc.M610318200","article-title":"Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor","volume":"282","author":"Oo","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118097_bib58","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbad218","article-title":"Uni-GBSA: an open-source and web-based automatic workflow to perform MM\/GB(PB)SA calculations for virtual screening","volume":"24","author":"Yang","year":"2023","journal-title":"Briefings Bioinf."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425008621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425008621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T20:06:31Z","timestamp":1772827591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425008621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":58,"alternative-id":["S0223523425008621"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118097","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery and SAR study of highly selective and potent 1,2,4-oxadiazole-based S1PR1 agonists","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118097","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118097"}}